Teva to Host Conference Call to Discuss Third Quarter 2021 Financial Results at 8 a.m. ET on October 27, 2021
02 October 2021 - 12:20AM
Business Wire
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)
announced today that it will issue a press release on its financial
results for the third quarter of 2021 on Wednesday, October 27,
2021 at 7:00 a.m. ET. Following the release, Teva will conduct a
conference call and live webcast on the same day, at 8:00 a.m.
ET.
In order to participate, please dial the following numbers:
United States 1-877-870-9135; Israel 1-809-213-985 or International
+44 (0) 2071 928338; passcode: 6466787.
A live webcast of the call will be available on Teva's website
at: http://ir.tevapharm.com/.
Following the conclusion of the call, a replay of the webcast
will be available within 24 hours on Teva's website or by calling
United States 1-866-331-1332; International +44 (0) 3333 009785;
passcode: 6466787.
About Teva Teva Pharmaceutical Industries Ltd. (NYSE and
TASE: TEVA) has been developing and producing medicines to improve
people’s lives for more than a century. We are a global leader in
generic and specialty medicines with a portfolio consisting of over
3,500 products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day, and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of specialty and biopharmaceutical
products. Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This document and the conference call may contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, which are based on
management’s current beliefs and expectations and are subject to
substantial risks and uncertainties, both known and unknown, that
could cause our future results, performance or achievements to
differ significantly from that expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our
ability to successfully compete in the marketplace; our substantial
indebtedness; our business and operations in general; compliance,
regulatory and litigation matters; other financial and economic
risks; and other factors discussed in our Annual Report on Form
10-K for the year ended December 31, 2020 and our Quarterly Reports
on Form 10-Q for the first and second quarters of 2021, including
in the sections captioned “Risk Factors.” Forward-looking
statements speak only as of the date on which they are made, and we
assume no obligation to update or revise any forward-looking
statements or other information contained herein, whether as a
result of new information, future events or otherwise. You are
cautioned not to put undue reliance on these forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211001005504/en/
IR Contacts Kevin C. Mannix (215) 591-8912 Yael Ashman
+972 (3) 914 8262
PR Contacts Kelley Dougherty (973) 832-2810 Yonatan Beker
(973) 917-0851
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Apr 2023 to Apr 2024